Zoetis Inc. $ZTS Position Reduced by Cidel Asset Management Inc.

Cidel Asset Management Inc. trimmed its position in Zoetis Inc. (NYSE:ZTS) by 97.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,408 shares of the company’s stock after selling 146,487 shares during the period. Cidel Asset Management Inc.’s holdings in Zoetis were worth $245,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Financial Engines Advisors L.L.C. boosted its stake in Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after buying an additional 87 shares in the last quarter. Physician Wealth Advisors Inc. raised its position in Zoetis by 17.4% in the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after acquiring an additional 91 shares in the last quarter. Smithfield Trust Co lifted its holdings in Zoetis by 4.2% in the 4th quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock valued at $290,000 after acquiring an additional 92 shares during the last quarter. Howland Capital Management LLC lifted its holdings in Zoetis by 4.5% in the 2nd quarter. Howland Capital Management LLC now owns 2,137 shares of the company’s stock valued at $333,000 after acquiring an additional 92 shares during the last quarter. Finally, Sapient Capital LLC boosted its position in shares of Zoetis by 4.7% during the 4th quarter. Sapient Capital LLC now owns 2,129 shares of the company’s stock valued at $269,000 after purchasing an additional 95 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. JPMorgan Chase & Co. dropped their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. TD Cowen dropped their price target on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Cantor Fitzgerald set a $94.00 price objective on Zoetis in a research report on Tuesday, August 25th. Finally, William Blair reissued a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $101.08.

Zoetis Stock Performance

Shares of ZTS opened at $73.05 on Friday. The company has a 50-day moving average of $75.56 and a two-hundred day moving average of $91.97. The stock has a market cap of $30.19 billion, a price-to-earnings ratio of 12.03, a PEG ratio of 1.70 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a one year low of $71.00 and a one year high of $150.05.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same quarter last year, the business posted $1.76 EPS. The company’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.